{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T07:20:04Z","timestamp":1794900004946,"version":"4.9.1"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"32","license":[{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,8]]},"abstract":"<jats:p>The purpose of this study was to evaluate the adverse events (AEs) associated with tucatinib by mining data from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) and explore potential drug-related AEs, thereby guiding safe clinical use. We extracted AE reports involving tucatinib from the FAERS database spanning from the 1st quarter of 2020 to the 4th quarter of 2024. The reports were categorized based on preferred terms and system organ classes, and risk signals were subsequently grouped for further analysis. Among 12,225 AEs listing tucatinib as the primary suspected drug, a total of 103 preferred terms for AEs were identified across 22 different system organ classes. In these reports, the proportion of females was higher than males (97.02% vs 1.26%), and the highest number of AEs was reported in the 45 to 59 years (15.29%). The median (interquartile range) time to AE onset was 30.00 days (8.00\u2013104.00). And the most of AEs occurred mainly within the 1st month (n\u2005=\u2005152, 26.16%) or &gt;60 days after drug administration (n\u2005=\u2005106, 18.24%). Among the numerous positive risk signals, such as diarrhea, nausea, vomiting, stomatitis, rash, palmar-plantar erythrodysesthesia syndrome, hepatotoxicity, anemia, and peripheral neuropathy exhibited high signal strength, which largely aligned with the current prescribing information. In addition, some AEs not explicitly mentioned in the package insert were also observed. These included platelet count abnormal, ejection fraction decreased, aortic valve incompetence, dehydration, hypokalemia, and various nail or skin-related problems (e.g., fingerprint loss, ingrowing nail, onychalgia, onychomadesis, skin discoloration\/hypertrophy\/hyperpigmentation\/exfoliation, pigmentation disorder, blister, etc), as well as nervous system disorders (e.g., memory impairment, brain edema, central nervous system lesion, hyperesthesia, taste disorder, emotional disorder) and paronychia. There is also a risk of various AEs in the treatment of tucatinib. In clinical application, it is so essential to monitor closely the dermatologic\/nail conditions, gastrointestinal issues, cardiovascular abnormalities, and neuropsychiatric manifestations. Should any adverse events occur or disease progression be observed, timely intervention is necessary to prevent severe organ damage and further disease deterioration.<\/jats:p>","DOI":"10.1097\/md.0000000000043778","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T19:02:01Z","timestamp":1755198121000},"page":"e43778","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Safety evaluation of tucatinib: Adverse event signal mining and analysis based on the FAERS database"],"prefix":"10.1097","volume":"104","author":[{"given":"Na","family":"Yang","sequence":"first","affiliation":[{"name":"Guizhou Nursing Vocational College, Guiyang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4861-7178","authenticated-orcid":false,"given":"Junxia","family":"Cao","sequence":"additional","affiliation":[{"name":"Guizhou Nursing Vocational College, Guiyang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261117","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13045-025-01660-y","article-title":"Global status and attributable risk factors of breast, cervical, ovarian, and uterine cancers from 1990 to 2021.","volume":"18","author":"Li","year":"2023","journal-title":"J Hematol Oncol"},{"key":"R2-20261117","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/ijc.35278","article-title":"The GLOBOCAN 2022 cancer estimates: data sources, methods, and a snapshot of the cancer burden worldwide.","volume":"156","author":"Filho","year":"2023","journal-title":"Int J Cancer"},{"key":"R3-20261117","doi-asserted-by":"crossref","first-page":"113371","DOI":"10.1016\/j.ejca.2023.113371","article-title":"Characterisation of luminal and triple-negative breast cancer with HER2 Low protein expression.","volume":"195","author":"Atallah","year":"2023","journal-title":"Eur J Cancer"},{"key":"R4-20261117","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1158\/1078-0432.CCR-20-3474","article-title":"FDA approval summary: pertuzumab, trastuzumab, and hyaluronidase-zzxf injection for subcutaneous use in patients with HER2-positive breast cancer.","volume":"27","author":"Gao","year":"2021","journal-title":"Clin Cancer Res"},{"key":"R5-20261117","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1158\/1078-0432.CCR-20-2701","article-title":"FDA approval summary: tucatinib for the treatment of patients with advanced or metastatic HER2-positive breast cancer.","volume":"27","author":"Shah","year":"2021","journal-title":"Clin Cancer Res"},{"key":"R7-20261117","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1158\/1078-0432.CCR-23-1041","article-title":"FDA approval summary: tucatinib with trastuzumab for advanced unresectable or metastatic, chemotherapy refractory, HER2-positive RAS wild-type colorectal cancer.","volume":"29","author":"Casak","year":"2023","journal-title":"Clin Cancer Res"},{"key":"R8-20261117","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jamaoncol.2022.5610","article-title":"Tucatinib vs placebo, both in combination with trastuzumab and capecitabine, for previously treated ERBB2 (HER2)-positive metastatic breast cancer in patients with brain metastases: updated exploratory analysis of the HER2CLIMB randomized clinical trial.","volume":"9","author":"Lin","year":"2023","journal-title":"JAMA Oncol"},{"key":"R9-20261117","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2174\/1574886313666181026100000","article-title":"Novel adverse events of iloperidone: a disproportionality analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) database.","volume":"14","author":"Subeesh","year":"2019","journal-title":"Curr Drug Saf"},{"key":"R10-20261117","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/17512433.2024.2306223","article-title":"Metformin adverse event profile: a pharmacovigilance study based on the FDA Adverse Event Reporting System (FAERS) from 2004 to 2022.","volume":"17","author":"Du","year":"2023","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R11-20261117","doi-asserted-by":"crossref","first-page":"103862","DOI":"10.1016\/j.breast.2024.103862","article-title":"Survival feature and trend of female breast cancer: a comprehensive review of survival analysis from cancer registration data.","volume":"79","author":"Tang","year":"2023","journal-title":"Breast"},{"key":"R12-20261117","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1038\/s41598-025-85954-8","article-title":"Long-term trends in the incidence of male breast cancer and nomogram for predicting survival in male breast cancer patients: a population-based epidemiologic study.","volume":"15","author":"Huang","year":"2025","journal-title":"Sci Rep"},{"key":"R13-20261117","doi-asserted-by":"crossref","first-page":"e2353331","DOI":"10.1001\/jamanetworkopen.2023.53331","article-title":"Breast cancer incidence among US women aged 20 to 49 years by race, stage, and hormone receptor status.","volume":"7","author":"Xu","year":"2023","journal-title":"JAMA Netw Open"},{"key":"R14-20261117","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12885-024-13336-w","article-title":"Epidemiology of breast cancer in Chinese women from 1990 to 2021: a systematic analysis and comparison with the global burden.","volume":"25","author":"Long","year":"2023","journal-title":"BMC Cancer"},{"key":"R15-20261117","doi-asserted-by":"crossref","first-page":"e37348","DOI":"10.1016\/j.heliyon.2024.e37348","article-title":"Sorafenib safety evaluation: real-world analysis of adverse events from the FAERS database.","volume":"10","author":"Ning","year":"2023","journal-title":"Heliyon"},{"key":"R16-20261117","doi-asserted-by":"crossref","first-page":"100063","DOI":"10.1016\/j.esmoop.2021.100063","article-title":"Tucatinib approval by EMA expands options for HER2-positive locally advanced or metastatic breast cancer.","volume":"6","author":"Corti","year":"2021","journal-title":"ESMO Open"},{"key":"R18-20261117","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.3390\/ijms25021064","article-title":"Molecular targeting of the Human Epidermal Growth Factor Receptor-2 (HER2) genes across various cancers.","volume":"25","author":"Rubin","year":"2024","journal-title":"Int J Mol Sci"},{"key":"R19-20261117","doi-asserted-by":"crossref","first-page":"155167","DOI":"10.1016\/j.phymed.2023.155167","article-title":"Protopanaxatriol activates EGFR and HER2 to strengthen the molecules of skin protection in human keratinocytes.","volume":"123","author":"You","year":"2023","journal-title":"Phytomedicine"},{"key":"R20-20261117","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/biolre\/ioz091","article-title":"Upregulation of AREG, EGFR, and HER2 contributes to increased VEGF expression in granulosa cells of patients with OHSS\u2020.","volume":"101","author":"Fang","year":"2019","journal-title":"Biol Reprod"},{"key":"R21-20261117","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s11912-021-01114-x","article-title":"Cardiovascular toxicity of novel HER2-targeted therapies in the treatment of breast cancer.","volume":"23","author":"Dent","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"R22-20261117","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1053\/j.seminoncol.2020.07.008","article-title":"Systemic therapy for metastatic HER2-positive breast cancer.","volume":"47","author":"Bredin","year":"2020","journal-title":"Semin Oncol"},{"key":"R23-20261117","doi-asserted-by":"crossref","first-page":"100892","DOI":"10.1016\/j.currproblcancer.2022.100892","article-title":"Tailoring antiHer2 treatment strategies in breast cancer and beyond.","volume":"46","author":"Fedele","year":"2022","journal-title":"Curr Probl Cancer"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000043778","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T07:02:12Z","timestamp":1794898932000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000043778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,8]]},"references-count":21,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000043778","relation":{},"ISSN":["1536-5964","0025-7974"],"issn-type":[{"value":"1536-5964","type":"electronic"},{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,8]]},"assertion":[{"value":"2025-04-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-18","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}